<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825253</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1831</org_study_id>
    <secondary_id>2006-005958-75</secondary_id>
    <nct_id>NCT00825253</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes</brief_title>
  <official_title>A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to compare the&#xD;
      pharmacodynamics (i.e. the glucose-lowering effect of the study medication over the entire&#xD;
      observation phase from the time of administration and the efficacy period) and the&#xD;
      pharmacokinetics (i.e. amount of the study insulin that can be determined in the blood) of a&#xD;
      treatment with biphasic insulin aspart 30 (BiAsp 30) administered once, twice or thrice daily&#xD;
      and biphasic human insulin 30 administered once daily in type 2 diabetic subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic human insulin 30</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. (Trial-related&#xD;
             activities are any procedure that would not have been performed during normal&#xD;
             management of the subject)&#xD;
&#xD;
          -  Type 2 diabetes mellitus diagnosed for at least 12 months prior to screening&#xD;
&#xD;
          -  HbA1c value between 7% and 10.5% (both inclusive) at screening&#xD;
&#xD;
          -  Any insulin treatment for at least 3 months prior to screening&#xD;
&#xD;
          -  Body mass index (BMI): 25 - 40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any oral antidiabetic agent within the past 6 months&#xD;
&#xD;
          -  Active proliferative retinopathy or maculopathy requiring treatment within 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Cardiac disease: NYHA class III or IV chronic heart failure (CHF), unstable angina,&#xD;
             and/or any myocardial infarction (treated or untreated) within 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Hepatic insufficiency (ALT or AST greater than or equal to 2 times the central&#xD;
             laboratory's upper reference limit)&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine greater than or equal to 1.6 mg/dL for males;&#xD;
             greater than or equal to&#xD;
&#xD;
          -  Recurrent hypoglycaemia or hypoglycaemic unawareness&#xD;
&#xD;
          -  Anaemia (haemoglobin less than 13.0 mg/dL in males and less than 12.0 mg/dL in&#xD;
             females) (WHO criteria)&#xD;
&#xD;
          -  Use of any systemic or topical medications (prescribed or non-prescribed) which may&#xD;
             alter glucose metabolism (other than insulin products), including but not limited to:&#xD;
             systemic or inhaled glucocorticoids, anabolic steroids, non-selective beta-blockers&#xD;
&#xD;
          -  History of substance (e.g. drugs, alcohol) abuse or a positive result in the urine&#xD;
             drug/alcohol screen or consumption of more than 14 units (women) or 21 units (men) of&#xD;
             alcohol per week (One unit of alcohol equals about 250 mL of beer or lager, one glass&#xD;
             of wine, or 20 mL spirits)&#xD;
&#xD;
          -  Smoking of more than 20 cigarettes per day and inability to refrain from smoking&#xD;
             during the in-house period&#xD;
&#xD;
          -  Known hepatitis or positive serological tests for the hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis C antibodies or HIV antibodies&#xD;
&#xD;
          -  Uncontrolled treated/untreated hypertension (systolic blood pressure greater than or&#xD;
             equal to 160 mmHg and/or diastolic blood pressure greater than or equal to 95 mmHg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Heise T, Heinemann L, HÃ¶velmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ. Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy. Diabetes Care. 2009 Aug;32(8):1431-3. doi: 10.2337/dc09-0097. Epub 2009 Jun 1.</citation>
    <PMID>19487640</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

